Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.59 |
| ▸ | CA2 | P00918 | 8/20 | 0.59 |
| ▸ | CA12 | O43570 | 6/20 | 0.59 |
| ▸ | CA9 | Q16790 | 6/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.59 |
| ▸ | CA7 | P43166 | 4/20 | 0.59 |
| ▸ | CA3 | P07451 | 3/20 | 0.59 |
| ▸ | CA4 | P22748 | 3/20 | 0.59 |
| ▸ | CA6 | P23280 | 3/20 | 0.59 |
| ▸ | CA5A | P35218 | 3/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.59 |
| ▸ | F2 | P00734 | 3/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447197 | 0.82 | CA2 (0.55) | CA1CA2CA12CA9CA14 | |
| Urea SCHEMBL27805729 | 0.80 | TSHR (0.74) | CA1CA2CA12CA9CA14 | |
| SCHEMBL29891245 | 0.80 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL29371266 | 0.80 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL30724830 | 0.80 | MAPK1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL11853542 | 0.77 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL29501073 | 0.76 | CA2 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL22038769 | 0.76 | POLB (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL11004638 | 0.76 | CA2 (0.62) | CA1CA2CA12CA9CA14 | |
| SCHEMBL3205770 | 0.76 | TSHR (0.79) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434720-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DIRMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8754233-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8410272-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1542997-B1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA CANADA INC (CA) | 2012-02-29 | — | — | EP | disclosed |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Valocor Therapeutics, Inc. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-7847101-B2 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | Valocor Therapeutics, Inc. (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | disclosed |
| EP-1542997-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, Inc. (CA) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004011460-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, INC. (CA) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | TST, PTK2, PTK2B | CA1 4436/4885CA2 1900/4885CA12 4797/4885 |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | REN, PGF, PKD1 | CA1 4853/4885CA2 1878/4885CA12 4741/4885 |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | CA1 4805/4885CA2 1890/4885CA12 4299/4885 |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | CA1 4805/4885CA2 1890/4885CA12 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.